In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Optimer Pharmaceuticals Inc.

Division of Merck & Co. Inc.
www.cubist.com

Latest From Optimer Pharmaceuticals Inc.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Deals M & A

Distortion And Inflation In Measuring Pharma M&A

Five companies in big pharma’s top 20 have come through mergers in the past 10 years or so that changed them significantly. As measured by standard financial performance parameters, the processes at Takeda and Teva (and to some extent, at Allergan) seem relatively smooth and productive. Those at Pfizer and Merck don’t. But it depends on how you look at the numbers.

Deals Business Strategies

CARB-X Partnership Puts Antibiotics' Future In Biotech Startups' Hands

The biotech startups that will be supported by a new transatlantic public-private partnership could end up with innovative products enticing enough to get some large biopharmaceutical firms back into the antibiotic game.

Clinical Trials Infectious Diseases

Amgen's Blincyto Is First Cancer Drug To Get Medicare Add-On Payments

CMS agrees to provide new technology add-on payments for Amgen’s cancer drug for acute lymphoblastic leukemia after the company documents Blincyto’s uniqueness and its advantages over existing treatments.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Merck & Co. Inc.
  • Senior Management
  • Hank McKinnell, PhD, Chmn. & CEO
    Stephen W Webster, SVP, Fin. & CFO
    Sherwood L Gorbach, MD, SVP, CSO
    Bhooshi De Silva, PhD, VP, International & Head, Bus. Dev.
  • Contact Info
  • Optimer Pharmaceuticals Inc.
    Phone: (201) 333-8819
    101 Hudson St., Ste. 3501
    Jersey City, NJ 07302
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register